Natalizumab, Fingolimod, and Dimethyl Fumarate and Pregnancy-Related Relapse and Disability in Multiple Sclerosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology 2021 Jun 15;96(24)e2989-e3002, WZ Yeh, PA Widyastuti, A Van der Walt, J Stankovich, E Havrdova, D Horakova, K Vodehnalova, S Ozakbas, S Eichau, P Duquette, T Kalincik, F Patti, C Boz, M Terzi, BI Yamout, J Lechner-Scott, P Sola, OG Skibina, M Barnett, M Onofrj, MJ Sá, PA McCombe, P Grammond, R Ampapa, F Grand'Maison, R Bergamaschi, DLA Spitaleri, V Van Pesch, E Cartechini, S Hodgkinson, A Soysal, A Saiz, M Gresle, T Uher, D Maimone, R Turkoglu, RM Hupperts, MP Amato, F Granella, C Oreja-Guevara, A Altintas, RA Macdonell, T Castillo-Trivino, H Butzkueven, R Alroughani, VG JokubaitisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.